Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADELE trial of adjuvant tislelizumab added to chemoradiation and chemotherapy for high-risk endometrial cancer
ACTRN12621000273886Phase 2Active, not recruiting
- Sponsor
- The University of Sydney
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of tislelizumab in endometrial cancer (EC) (2 arms), sponsored by The University of Sydney. Primary endpoint: Failure-free survival at 12 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ACTRN12621000273886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000273886.